Tryp Therapeutics Inc.

Recent News

  • Tryp Therapeutics reicht IND-Antrag für klinische Phase-2a-Studie bei Fibromyalgie ein

    San Diego, California--(Newsfile Corp. - Donnerstag, 4. November 2021) - Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) ("Tryp" oder das "Unternehmen"), ein Pharmaunternehmen mit Fokus auf der Entwicklung von Psilocybin-basierten Verbindungen für Krankheiten mit ungedecktem medizinischem Bedarf, gab heute bekannt, dass es einen Antrages für ein neues Prüfpräparat ("IND") bei der US-amerikanischen Food and Drug Administration ("FDA)" zur Bewertung ihres klinischen Kandidaten TRP-8802 in einer klinischen Phase-2a-Studie eingereicht hat, die in Zusammenarbeit mit der University of Michigan die Sicherheit und vorläufige...

    2021-11-04 11:02 AM EDT
  • Tryp Therapeutics to Participate in Wonderland: Miami on November 8

    San Diego, California--(Newsfile Corp. - November 4, 2021) - - Nov. 4, 2021 - Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) ("Tryp" or the "Company"), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs, announced today that the Company will participate in Wonderland: Miami, presented by Microdose, on November 8, 2021. The conference will take place on November 8-9, 2021 in Miami, Florida. Greg McKee, Chairman and CEO, will participate in a panel discussion entitled,...

    2021-11-04 7:05 AM EDT
  • Tryp Therapeutics Submits IND Application for Phase 2a Clinical Trial in Fibromyalgia

    San Diego, California--(Newsfile Corp. - November 2, 2021) - Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) ("Tryp" or the "Company"), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs, announced today that it has submitted an Investigational New Drug ("IND") application to the U.S. Food and Drug Administration ("FDA") to evaluate its clinical candidate, TRP-8802, in a Phase 2a clinical trial that investigates safety and preliminary effectiveness of psilocybin-assisted therapy among patients with fibromyalgia in collaboration...

    2021-11-02 7:05 AM EDT
  • Tryp Therapeutics to Present at 15th Annual Pain Therapeutics Summit

    San Diego, California--(Newsfile Corp. - October 26, 2021) - Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) ("Tryp" or the "Company"), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs, today announced that the Company will present at the 15th Annual Pain Therapeutics Summit on November 1, 2021 at 12:15 p.m. EDT.The virtual conference will take place on November 1-3, 2021. Greg McKee, Chairman and CEO, will provide an overview of the Company followed by a live...

    2021-10-26 7:05 AM EDT
  • Tryp Therapeutics Reports Clinical Hold on Proposed Phase 2a Study in Eating Disorders

    San Diego, California--(Newsfile Corp. - October 20, 2021) - Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) ("Tryp" or the "Company"), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs, today announced that the U.S. Food and Drug Administration ("FDA") has placed a clinical hold on the Company's Phase 2a study for eating disorders that includes binge eating disorder and hypothalamic obesity. The notification from the FDA did not provide a reason for the clinical hold...

    2021-10-20 7:00 PM EDT
  • Tryp Therapeutics Announces Inclusion in AdvisorShares Psychedelics ETF

    San Diego, California--(Newsfile Corp. - October 14, 2021) - Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) ("Tryp"), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs, announced today its inclusion in the AdvisorShares Psychedelics ETF (the "Fund"), currently trading under the ticker symbol "PSIL" on the NYSE Arca exchange.The Fund is actively trading and focuses on companies that devote a majority of assets to psychedelic drug development. The Fund was launched in September of this year...

    2021-10-14 7:05 AM EDT
  • Tryp Therapeutics to Present at the KSCA Psychedelics Virtual Investor Conference

    San Diego, California--(Newsfile Corp. - October 12, 2021) - Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) ("Tryp" or the "Company"), a pharmaceutical company developing psilocybin-based compounds for diseases with unmet medical needs, announced today that it will present at the KCSA Psychedelics Virtual Investor Conference on October 14, 2021 at 3:00 p.m. EDT.The conference will be held virtually on October 13-14, 2021. Luke Hayes, Chief Financial Officer, will provide a live overview of Tryp's activities and elaborate on how the Company...

    2021-10-12 7:15 AM EDT
  • Tryp Therapeutics Announces Collaboration with Researchers at the University of Wisconsin-Madison

    San Diego, California--(Newsfile Corp. - October 7, 2021) - Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) ("Tryp" or the "Company"), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs, announced today a collaboration with Paul Hutson, PharmD and Christopher Nicholas, PhD to support clinical pharmacology studies for the Company's proprietary drug product, TRP-8803.Dr. Hutson and Dr. Nicholas will serve as Investigators on a clinical pharmacology study to evaluate the safety and pharmacokinetics of TRP-8803 in healthy,...

    2021-10-07 7:05 AM EDT